2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Leukemia, Myeloid, Acute
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Noonan Syndrome 5
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Liver Neoplasms
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Early Hormone Receptor-positive Breast Cancer
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Interventions
Echocardiography
4
sacubitril and valsartan sodium hydrate drug combination
3
Standard of Care
3
Nutrition Assessment
3
Exercise
3
Electrocardiography
3
Carvedilol
3
dapagliflozin
2
Surveys and Questionnaires
2
Spironolactone
2
Rituximab
2
Lenalidomide
2
Ivabradine
2
Control Groups
2
Blood Specimen Collection
2
Atorvastatin
2
Adrenergic beta-Antagonists
2
ziprasidone
1
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Zolpidem
1
Watchful Waiting
1
Warfarin
1
Vincristine
1
Vecuronium Bromide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Heart Failure
×
Antineoplastic Agents
×
Clear all
NCT03882580
2023-04-24
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Unknown
5,000 enrolled